References
- Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Int. J. Cancer128, 1813–1821 (2011).
- Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr. Relat. Cancer12, S47–S59 (2005).
- Britton DJ, Hutcheson IR, Knowlden JM et al. Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res. Treat.96, 131–146 (2006).
- Osborne R, Merlo GR, Mitsudomi T et al. Mutations in the p53 gene in primary human breast cancers. Cancer Res.51, 6194–6198 (1991).
- Olivier M, Langerød A, Carrieri P et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res.12(4), 1157–1167 (2006).
- Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene26(15), 2157–2165 (2007).
- Miller LD, Smeds J, George J et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl Acad. Sci. USA102(38), 13550–13555 (2005).
- Coutant C, Rouzier R, Qi Y et al. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin. Cancer Res.17(8), 2591–2601 (2011).
- Shirley SH, Rundhaug JE, Tian J et al. Transcriptional regulation of estrogen receptor-α by p53 in human breast cancer cells. Cancer Res.69(8), 3405–3414 (2009).
- Fuchs-Young R, Shirley SH, Lambertz I et al. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res. Treat. DOI: 10.1007/s10549-010-1308-y (2010) (Epub ahead of print).
- Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer9(9), 631–643 (2009).
- Bedard PL, Freedman OC, Howell A, Clemons M. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? Breast Cancer Res. Treat.108(3), 307–317 (2008).